Skip to content

Kura Oncology KURA Ratios & Valuation

FY'25FY'24FY'23FY'22
Profitability
Operating margin-449.9%-91.4pp-358.5%
Net margin-412.9%-90.1pp-322.9%
EBITDA margin-448.4%-91.4pp-357%
Returns
Return on equity-94.8%-51.9pp-42.9%-5.6pp-37.3%-8.0pp-29.3%-6.0pp
Return on assets-37.2%-8.4pp-28.8%+4.9pp-33.7%-6.3pp-27.4%-5.3pp
Return on invested capital-241.7%-175pp-66.3%-22.6pp-43.7%-8.9pp-34.7%
Efficiency
Asset turnover0.1×0.0×0.1×
Liquidity
Current ratio6.1×-3.4×9.5×-2.8×12.3×-6.3×18.6×-4.7×
Quick ratio6.1×-3.4×9.5×-2.8×12.3×-6.3×18.6×-4.7×
Cash ratio1.3×-1.6×2.9×+1.8×1.1×-1.1×2.2×-1.9×
Leverage
Debt-to-equity0.1×+0.1×0.0×0.0×0.0×
Debt-to-assets0.0×0.0×0.0×0.0×
Interest coverage-200.8×-81.5×-119.3×-12.3×-107×+504×-610.8×
Per Share
Book value per share$1.99-58.6%$4.80-11.5%$5.43-13.5%$6.27-17.8%
Valuation
Market capitalization$919.7M+81.6%$677.32M-39.1%$1.11B+32.2%$841.16M-9.8%
Enterprise value$904.89M+90.7%$469.45M-57.0%$1.09B+35.9%$803.38M-5.3%
Price / sales12.8×+3.5×12.6×
Price / book8.5×+7.1×1.6×-1.2×2.8×+0.8×+0.2×
EV / sales12.6×+3.9×8.7×
Earnings yield-32%+3.9pp-25.7%-12.0pp-13.7%+2.4pp-16.1%-2.2pp

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where do Kura Oncology's ratios come from?
Every ratio is computed from Kura Oncology's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.